Streetbeat News

Price Targets

VSTM

Truist Securities analyst Srikripa Devarakonda maintains a 'Buy' rating on Verastem (NASDAQ:VSTM) but has lowered the price target from $60 to $39.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 12:11 pm

ASR

Goldman Sachs analyst Bruno Amorim has downgraded Grupo Aeroportuario (NYSE:ASR) from Neutral to Sell and lowered the price target from $282 to $28.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:11 pm

IPA

Benchmark analyst Robert Wasserman has reiterated a Speculative Buy on ImmunoPrecise Antibodies (NASDAQ:IPA) and maintained a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 12:09 pm

AAPL

ABNB

BX

CSX

FMC

HCA

JPM

MPC

NVDA

SNOW

XPO

Several US-listed companies have had their price targets adjusted by various analysts. Keybanc raised NVIDIA's price target from $500 to $550, while Credit Suisse lowered FMC Corporation's target from $120 to $101. Other companies with adjusted targets include Snowflake, Blackstone, XPO, HCA Healthcare, CSX Corporation, Marathon Petroleum, Apple, JPMorgan Chase, and Airbnb.

Portfolio Pulse from Lisa Levin

July 11, 2023 | 11:59 am

SGRY

Mizuho analyst Ann Hynes maintains a 'Buy' rating on Surgery Partners (NASDAQ:SGRY) and raises the price target from $48 to $50.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:55 am

HLLY

Benchmark analyst John Lawrence has reiterated a 'Buy' rating on Holley (NYSE:HLLY) and maintained a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 11:54 am

CVS

Mizuho analyst Ann Hynes has maintained a 'Buy' rating on CVS Health (NYSE:CVS), but lowered the price target from $120 to $88.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:53 am

TECK

Benchmark analyst Nathan Martin has reiterated a 'Buy' rating on Teck Resources (NYSE:TECK) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 11:53 am

UNH

Mizuho analyst Ann Hynes maintains a 'Buy' rating on UnitedHealth Group (NYSE:UNH) but lowers the price target from $600 to $549.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:53 am

VRDN

JMP Securities analyst Jason Butler has reiterated a Market Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $44 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 11:52 am